CH5424802 is a selective ALK inhibitor developed for the treatment of non-small cell lung cancer (NSCLC) that expresses anaplastic lymphoma kinase (ALK) gene rearrangements. It is particularly effective against tumors harboring the ALK fusion protein, which drives cancer cell proliferation and survival. The compound demonstrates potent antitumor activity in ALK-positive cancer models and has shown efficacy in patients who have developed resistance to earlier-generation ALK inhibitors. Its ability to penetrate the blood-brain barrier makes it especially valuable in managing brain metastases, a common complication in advanced NSCLC. Clinical development has focused on its use in both treatment-naïve and previously treated patients, with studies evaluating optimal dosing, safety, and long-term outcomes.